Literature DB >> 2425050

Human and monoclonal antibodies to hepatitis B core antigen recognise a single immunodominant epitope.

R B Ferns, R S Tedder.   

Abstract

Monoclonal antibodies were raised against hepatitis B core antigen (HBcAg) synthesized in Escherichia coli. They identified a single immunodominant determinant on both liver-derived and E. coli-derived HBcAg. Cross-inhibition studies demonstrated that HBsAg-containing human sera which contained antibodies to HBcAg (anti-HBc) together with either hepatitis B e antigen (HBeAg) or its antibody (anti-HBe) essentially only recognised the same single determinant as the murine antibodies. The identification of a single dominant HBcAg determinant may be important if future hepatitis B virus vaccines contain HBcAg.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425050     DOI: 10.1002/jmv.1890190213

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

1.  Diversity of core antigen epitopes of hepatitis B virus.

Authors:  D M Belnap; N R Watts; J F Conway; N Cheng; S J Stahl; P T Wingfield; A C Steven
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-03       Impact factor: 11.205

2.  Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids.

Authors:  Norman R Watts; Giovanni Cardone; Joe G Vethanayagam; Naiqian Cheng; Catharina Hultgren; Stephen J Stahl; Alasdair C Steven; Matti Sällberg; Paul T Wingfield
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

3.  Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens.

Authors:  M Sällberg; K Townsend; M Chen; J O'Dea; T Banks; D J Jolly; S M Chang; W T Lee; D R Milich
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Sizing up large protein complexes by electrospray ionisation-based electrophoretic mobility and native mass spectrometry: morphology selective binding of Fabs to hepatitis B virus capsids.

Authors:  Jessica Z Bereszczak; Marlene Havlik; Victor U Weiss; Martina Marchetti-Deschmann; Esther van Duijn; Norman R Watts; Paul T Wingfield; Guenter Allmaier; Alasdair C Steven; Albert J R Heck
Journal:  Anal Bioanal Chem       Date:  2013-12-20       Impact factor: 4.142

5.  IgG subclasses in circulating immune complexes with hepatitis B e antigen in chronic hepatitis B.

Authors:  M Sällberg; H Norder; G Lindh; L O Magnius
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

6.  Immunodominant regions within the hepatitis C virus core and putative matrix proteins.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

7.  Epitope-distal effects accompany the binding of two distinct antibodies to hepatitis B virus capsids.

Authors:  Jessica Z Bereszczak; Rebecca J Rose; Esther van Duijn; Norman R Watts; Paul T Wingfield; Alasdair C Steven; Albert J R Heck
Journal:  J Am Chem Soc       Date:  2013-04-18       Impact factor: 15.419

8.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  The quaternary structure, antigenicity, and aggregational behavior of the secretory core protein of human hepatitis B virus are determined by its signal sequence.

Authors:  H J Schlicht; G Wasenauer
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  A cysteine and a hydrophobic sequence in the noncleaved portion of the pre-C leader peptide determine the biophysical properties of the secretory core protein (HBe protein) of human hepatitis B virus.

Authors:  G Wasenauer; J Köck; H J Schlicht
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.